Viewing entries tagged
RF-5

Alan Bernstein

Alan Bernstein

Adjunct Professor

Address:
Canadian Institute for Advanced Research, Suite 505
MaRS West Tower, 661 University Ave.
Toronto, ON M5G 1M1

Phone #: 416-971-4255

Web Site: http://www.cifar.ca/cifar-staff


Research:

Intersection of research and public policy, especially science policy


Education

Postdoctoral Fellow:  Imperial Cancer Research Laboratories, U.K.
M.Sc, Ph.D.:  University of Toronto
B.Sc.:  University of Waterloo


Fields of Interest:

  • Genetic Models of Development and Disease

  • Molecular Medicine and Human Genetics

 

Research Interests:

My current research interests centre around the intersection of research and public policy, especially with regard to science policy.

 

 

Marc Fiume

Marc Fiume.png

Marc Fiume, Ph.D.

Adjunct Professor

Address:
DNAstack
Suite 1300, 661 University Ave.
Toronto, ON M5G 1M1


Education

B.Sc., M.Sc., Ph.D.:  University of Toronto

Fields of Interest:

Dr. Marc Fiume is an eminent professional of recognized stature, with a remarkable track record in science and business, and is a highly regarded entrepreneur, researcher, and thought-leader in genomics committed to developing standards and technologies that accelerate the realization of precision health and medicine.  He is currently Founder and CEO at DNAstack, a company located in the MaRS West Tower that is highly engaged and collaborative with the local Toronto genomics community.

 

 

David Sealey

DavidSealey_.png

David Sealey, Ph.D.

Adjunct Professor

Address:
Janssen Inc.
19 Green Belt Drive
Toronto, ON M3C 1L9


Education

Ph.D.:  University of Toronto
B.Sc.:  University of Toronto


Fields of Interest:

  • Graduate Professional Development

Dr. David Sealey is Associate Director of Regulatory Affairs at the Janssen Pharmaceutical Companies of Johnson & Johnson. At Janssen, David has guided drug development programs at various stages from pre-clinical to marketing authorization to post-marketing. He previously held a position in Medical Affairs, and has covered multiple therapeutic areas including oncology, immunology, and virology. Prior to Janssen, David worked as a consultant developing medical education content and scientific articles for pharmaceutical companies, scientists and healthcare professionals. David trained as a cancer biologist at the Campbell Family Institute for Breast Cancer Research/Ontario Cancer Institute. He holds a Ph.D. (Medical Biophysics) and Hon.B.Sc. (Pharmacology) from the University of Toronto. David has been a mentor to students through University College, the Life Sciences Career Development Society, and the Science Career Impact Project (sciencecareerimpact.org) – a volunteer organization that he co-founded to deliver transformational experiences to sciences trainees seeking careers in industry.

Bruce Seet

Bruce Seet.jpg

Bruce Seet, Ph.D.

Adjunct Professor

Address:
Sanofi Pasteur, Connaught Campus
1755 Steeles Avenue West, Building 83, Room 264
Toronto, ON M2R 3T4


Education

Postdoctoral Fellow:  University of Toronto
M.B.A., Ph.D.:  University of Toronto
B.Sc.:  Western University


Fields of Interest:

  • Graduate Professional Development

Dr. Bruce Seet brings his diverse background and experience to the Department of Molecular Genetics to enhance the professional development of graduate-level trainees. Bruce earned a B.Sc (Honours Human Physiology) and a Ph.D. (Microbiology and Immunology) from Western University (London, Canada), followed by a postdoctoral research fellowship at the Lunenfeld Research Institute at Mt. Sinai Hospital (Toronto). After a decade of research in academia, Dr. Seet joined GlaxoSmithKline (GSK) in 2006 where he held a variety of roles over 8 years. While at GSK, he completed his MBA at the Rotman School of Management (Toronto). He joined Sanofi Pasteur in 2014 where he resides presently as a Director of Medical Affairs. Among his volunteer activities, Bruce serves as a mentor and coach to young scientists and is the President and founder of the Science to Business Network (www.s2bn.org), a grass-roots organization formed in 2011 that promotes the professional development of young scientists as well as innovation in Canada by connecting industry and academia. He also serves on the Research Management Committee as well as the HQP Development Committee for BioCanRx, a Network Centres of Excellence (NCE) that accelerates the clinical development of promising cancer immunotherapies in Canada.

 

 

Frédéric Sweeney

Sweeney.jpg

Frédéric Sweeney, Ph.D.

Adjunct Professor

Address:
Northern Biologics, Inc.
1 Marina Park Drive, Suite 1410
Boston, MA USA 02210


Education

Ph.D.:  University of Toronto
B.Sc.:  McGill University

Frédéric Sweeney joined bioMérieux in February of 2016 as Vice-President of Corporate Development and Strategic Financing Lead.  bioMérieux is a Euronext listed company, with a majority ownership by the Mérieux Family, headquartered in Marcy L'Étoile (Lyon area, France). A world leader in the field of in vitro diagnostics for over 50 years, the company is established in 150 countries with annual revenues of € 2,103 billion and employs  9,800 people around the world.  Fred’s role at bioMérieux is to lead new technology search and evaluation and to establish strategic partnerships (R&D collaboration, licensing, co-development, investments, M&A).  He is also responsible for all aspects of bioMerieux’ strategic investments in early stage companies.  Fred holds Board of Directors positions at Banyan Biomarkers (San Diego, CA, USA), Qvella Corporation (Toronto, ON, Canada), Lumed (Sherbrooke, QC, Canada) and Virgin Instruments (Marlborough, MA, USA).

Prior to bioMérieux, Fred was Head of Business Development and Strategy at T2 Biosystems, a Boston-based high growth, early stage commercial company developing innovative diagnostic solutions.  As part of his role at T2 Bio, Fred was involved in private capital raises, establishing key strategic partnerships, and the initial public offering of TTOO on NASDAQ.

Before moving to Boston, Fred was part of the founding team of Tornado Spectral Systems, a Toronto-based company developing and manufacturing high-performance optical spectroscopy instrumentation.  He started his career as part of the life sciences investment team of VenGrowth Private Equity Partners, a large Toronto-based Venture Capital and Private Equity firm.

A graduate of the Molecular and Medical Genetics Department of the University of Toronto, Fred obtained his PhD as one of the first students of Dr. Daniel Durocher where he was a Terry Fox Awardee and studied the molecular mechanisms of the DNA damage checkpoint response.